The global clinical trial imaging market was valued at USD 1.53 Billion in 2025, driven by the increasing prevalence of cancer and cardiovascular diseases and growing importance of precision imaging across the globe. The market is anticipated to grow at a CAGR of 7.80% during the forecast period of 2026-2035 to achieve a value of USD 3.24 Billion by 2035.
Base Year
Historical Period
Forecast Period
Rising demand for personalized medicine and precision imaging is accelerating clinical trial imaging adoption to support more accurate, targeted drug development and patient stratification.
Growing investments in drug development, especially for oncology and rare diseases, are boosting the need for advanced imaging solutions to assess treatment efficacy and disease progression.
Integration of AI and cloud-based platforms in imaging analytics is enhancing trial efficiency, reducing costs, and improving data accuracy, thereby propelling market growth globally.
Compound Annual Growth Rate
7.8%
Value in USD Billion
2026-2035
*this image is indicative*
Clinical trial imaging refers to the use of medical imaging technologies such as MRI, CT scans, PET scans, and ultrasound to gather crucial data during clinical research. These imaging techniques help evaluate the safety, efficacy, and biological effects of new drugs, therapies, or medical devices. By offering non-invasive visual insights into anatomical and functional changes, clinical trial imaging supports accurate diagnosis, monitoring, and endpoint assessment. It plays a vital role in areas like oncology, neurology, and cardiology, where precise visual evidence is key to regulatory approval and improved patient outcomes.
Digital Advancements to Drive Market Growth
The growing need for high-resolution imaging, automation of radiology workflows, and integration of AI in image interpretation are significant drivers in the market. For instance, in December 2024, Konica Minolta Healthcare Americas, Inc. unveiled several new digital radiography (DR) solutions at RSNA 2024, including Bone Suppression Imaging (BSI) for chest X-rays. Recently FDA-cleared, BSI enhances lung visibility by suppressing rib and clavicle structures. The new AeroDR PDR flat panel detector also targets budget-conscious facilities seeking modernisation. These innovations are expected to boost clinical trial imaging by improving diagnostic precision, streamlining workflows, and expanding access to advanced imaging tools in diverse healthcare settings.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Technological Innovations to Boost Clinical Trial Imaging Market Value
With increasing emphasis on real-time imaging and seamless data integration in clinical trials, innovative imaging platforms and robust PACS systems are gaining traction. For instance, in February 2024, aycan supported Enspectra Health’s clinical trial by preparing DICOM data from the FDA-cleared VIOTM System, a breakthrough tool for visualising skin cellular structures in real-time. Aycan's PACS, viewers, and expert services ensured clinical trial readiness. This development highlights the expanding role of imaging technology providers in trial data management. Such innovations are poised to accelerate trial timelines, improve imaging precision, and bolster market demand for sophisticated imaging infrastructure in dermatological and related research areas.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Clinical Trial Imaging Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Offerings
Market Breakup by Modality
Market Breakup by Therapeutic Areas
Market Breakup by End User
Market Breakup by Region
Services Segment to Lead the Share by Offerings
The services segment is poised to lead the market owing to rising demand for expert image interpretation, trial design consultation, and end-to-end operational imaging services. These offerings reduce complexity and ensure regulatory compliance, especially in multicentre studies. Increased outsourcing of imaging operations by pharmaceutical and biotechnology companies has further accelerated demand. With growing reliance on precision medicine and complex trial protocols, trial-specific imaging support services are becoming indispensable. This segment’s adaptability to diverse imaging needs and technological integration is expected to significantly propel the market share during the forecast period.
Magnetic Resonance Imaging to Hold a Substantial Share by Modality
Magnetic resonance imaging (MRI) is expected to hold the largest share in the market due to its superior contrast resolution and detailed soft tissue imaging. MRI is vital in neurology, oncology, and musculoskeletal trials, offering accurate and non-invasive assessment without ionising radiation. Increasing neurological and cancer research is fuelling its adoption. As per the analysis by Expert Market Research, the market is expected to grow at a CAGR of 6.20% during the forecast period of 2025-2034. The modality also supports functional imaging, aiding in the development of innovative therapies. Technological advancements in MRI sequences and the integration of AI for image analysis further strengthen its relevance, ensuring its dominance in clinical trials over the coming years.
Oncology to Lead the Segmentation by Therapeutic Areas
Oncology is anticipated to dominate the therapeutic areas segment due to the global surge in cancer clinical trials and rising investments in novel cancer therapies. Imaging is critical for tumor detection, progression monitoring, and treatment response evaluation. Modalities like CT, MRI, and PET scans are integral to oncology trials, enhancing precision and aiding in robust endpoint assessments. As per the analysis by Expert Market Research, the global computed tomography market is likely to grow at a rate of 6.00% during the forecast period of 2025-2034. As personalized cancer treatments expand, imaging-guided approaches become indispensable for accurate patient stratification and efficacy validation. This ongoing emphasis on cancer drug development will continue driving the demand for imaging services and technologies in oncology-related clinical trials.
Biotechnology and Pharmaceutical Companies to Hold a Significant Share by End User
Biotechnology and pharmaceutical companies are projected to hold the largest market share by end user, as they remain the primary sponsors of clinical trials globally. With increasing pressure to reduce time-to-market and meet stringent regulatory requirements, these companies increasingly rely on advanced imaging to validate therapeutic efficacy and safety. Imaging plays a crucial role in supporting clinical endpoints and biomarker evaluation. Moreover, the shift toward personalised medicine and biologics is pushing for more imaging-centric trial designs. Their substantial investment capacity and strategic focus on innovation ensure continued dominance of this end-user segment in the forecast period.
North America is poised to lead the market due to its high concentration of pharmaceutical giants, early adoption of advanced imaging technologies, and a robust clinical research infrastructure. The region also benefits from strong regulatory support and extensive funding for R&D initiatives, which fosters innovation in imaging solutions for drug development. Additionally, the rising demand for decentralised clinical trials and AI-powered imaging analytics enhances North America's leadership position. Europe follows with its established CRO network and focuses on oncology trials. Asia-Pacific is rapidly emerging, driven by expanding clinical research in China and India, while Latin America and the Middle East and Africa are witnessing moderate growth due to increasing clinical trial participation and improving healthcare infrastructure.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Princeton, New Jersey, Navitas Life Sciences was established in 1984. The company offers end-to-end clinical research services, including imaging, across various therapeutic areas. Navitas delivers operational imaging solutions, AI-powered data analytics, and regulatory expertise to accelerate drug development timelines. It caters to both large pharmaceutical firms and emerging biotechs by integrating clinical trial imaging into broader data-driven strategies. Its global infrastructure and deep therapeutic knowledge ensure effective management of complex imaging trials, helping clients maintain compliance, improve accuracy, and enhance overall clinical trial outcomes.
Founded in 1994 and headquartered in Malvern, Pennsylvania, BioTelemetry, a part of Philips, specialises in remote patient monitoring and diagnostic services, including clinical trial imaging solutions. The company offers mobile cardiac telemetry and holter monitoring systems, which are vital for cardiovascular imaging trials. BioTelemetry supports clinical studies through real-time imaging data collection, precise image interpretation, and streamlined data transmission, ensuring faster insights and regulatory compliance. Its robust digital platforms and scalable technology infrastructure make it a preferred partner in cardiovascular and chronic disease-focused clinical research globally.
Established in 1990 and headquartered in Dublin, Ireland, ICON PLC is a leading global CRO offering full-spectrum clinical development services, including advanced imaging solutions. ICON provides operational imaging services, read analysis, trial design consulting, and technical support across multiple therapeutic areas. Its imaging expertise supports oncology, neurology, and rare disease trials through AI-integrated platforms, centralised image review, and real-time data analytics. With a strong global footprint and a client-focused approach, ICON enables pharmaceutical and biotechnology firms to optimise imaging protocols, enhance trial accuracy, and expedite regulatory submissions.
Founded in 2004 and based in London, United Kingdom, IXICO PLC is a neuroimaging specialist serving the clinical trial market. The company provides advanced imaging services and AI-driven analytics specifically for neurological conditions such as Alzheimer’s, Parkinson’s, and Huntington’s disease. IXICO offers solutions including read analysis, central image management, and biomarker quantification using MRI, PET, and other imaging modalities. Its expertise in neurodegenerative disorders and precision imaging supports early diagnosis and disease monitoring. IXICO's contributions are vital in improving the accuracy, speed, and outcome predictability of neurological clinical trials worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include ProScan Imaging, Radiant Sage LLC, Cardiovascular Imaging Technologies, Biomedical Systems Corp, Clario, and WCG Clinical.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Offerings |
|
| Breakup by Modality |
|
| Breakup by Therapeutic Areas |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share